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Abstract 
Context: Mutations in the immunoglobulin superfamily, member 1 (IGSF1) gene cause the X-linked 
IGSF1 deficiency syndrome consisting of central hypothyroidism, delayed pubertal testosterone rise, 
adult macroorchidism, variable prolactin deficiency, and occasionally transient partial GH deficiency. 
Since our first reports, we discovered 20 new families with 18 new pathogenic IGSF1 mutations. 
65 
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Objective: We aimed to share data on the largest cohort of patients with IGSF1 deficiency to date and 
formulate recommendations for clinical management. 
69 
70 
Methods: We collected clinical and biochemical characteristics of 69 male patients (35 children, 34 
adults) and 56 female IGSF1 mutation carriers (3 children, 53 adults) from 30 unrelated families 
according to a standardized clinical protocol. At evaluation, boys were treated with levothyroxine in 
89%, adult males in 44%, and females in 5% of cases. 
71 
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Results: Additional symptoms in male patients included small thyroid gland volume (74%), high birth 
weight (25%), and large head circumference (20%). In general, the timing of pubertal testicular 
growth was normal or even premature, in contrast to a late rise in testosterone levels. Late adrenarche 
was observed in patients with prolactin deficiency, and adult DHEA concentrations were decreased in 
40%. Hypocortisolism was observed in 6 of 28 evaluated newborns, although cortisol concentrations 
were normal later on. Waist circumference of male patients was increased in 60%, but blood lipids 
were normal. Female carriers showed low FT4 and low-normal FT4 in 18% and 60%, respectively, 
delayed age at menarche in 31%, mild prolactin deficiency in 22%, increased waist circumference in 
57%, and a negative correlation between FT4 concentrations and metabolic parameters.  
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Conclusion: IGSF1 deficiency represents the most common genetic cause of central hypothyroidism 
and is associated with multiple other characteristics. Based on these results, we provide 
recommendations for mutational analysis, endocrine work-up,  and long-term care.
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Context 
We previously reported that loss-of-function mutations in the immunoglobulin superfamily, member 1 
(IGSF1) gene in eleven families causes the X-linked IGSF1 deficiency syndrome (1). In males the 
phenotype is characterized by congenital central hypothyroidism, delayed testosterone rise in puberty 
but normal timing of testicular enlargement, adult macroorchidism, partial GH deficiency (GHD) in 
some patients during childhood (but with high-normal IGF-1 concentrations in adulthood) or lifelong 
prolactin deficiency, and overweight habitus (1-5). A minority of female heterozygous carriers 
exhibits central hypothyroidism (2).  
IGSF1 encodes a plasma membrane glycoprotein, and all described IGSF1 mutations reported to 
date impair proper glycosylation and trafficking of the protein to the cell surface (1). Furthermore, 
Igsf1-deficient male mice show reduced serum TSH and T3 concentrations, decreased pituitary Trhr 
mRNA levels, and show larger body size and weight than wild-type mice (1). Yet, IGSF1’s specific 
local function remains enigmatic. 
Within three years after the discovery of this syndrome, we have identified 20 new families 
carrying 18 new mutations. In order to provide a more precise description of the clinical 
characteristics of IGSF1 deficiency, a total of 69 male patients and 56 female carriers were invited for 
clinical characterization according to a defined uniform protocol. This allowed us to formulate 
recommendations for the clinical management of these patients.
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Subjects and methods 
Design 
In this descriptive case series, we present data on the clinical and biochemical characteristics of 
pediatric and adult hemizygous male patients with a mutation in IGSF1, and of adult female 
heterozygous carriers. Data were collected according to a clinical protocol approved by the Medical 
Ethics Committee of the Leiden University Medical Center. All subjects gave written informed 
consent.  
 
Subjects 
All patients in whom our group identified a pathogenic mutation in IGSF1 were invited for additional 
investigations. We collected data on 35 boys (mean age 9.8 yr, range 0.2-17.6 yr), 34 male adults (48 
yr, 18-88 yr), 3 girls (9.9, 12.2, and 16.4 yr), and 53 female adults (48 yr, 21-81 yr) from 30 unrelated 
families carrying IGSF1 mutations. The families were from the Netherlands (n=16), the UK (n=3), 
Italy (n=4), Morocco (n=2), and Argentina, Belgium, Canada, Israel, and the USA (n=1 each). Some 
characteristics of 24 males and 18 females from ten families within this cohort were previously 
reported (2), but were supplemented with additional data. Fifteen of 34 male adults were treated with 
levothyroxine at current evaluation, as were 31 of 35 male children, and 3 of 56 females. All others 123 
either chose not to be treated with levothyroxine in the absence of complaints, or had not yet started 124 
treatment after the detection of hypothyroidism in the course of our analysis of family members of 125 
probands. Pathogenicity of the variants was determined based on the presence of central 
hypothyroidism with proper phenotype-genotype segregation, and in silico and in vitro analysis of the 
mutated proteins, as previously described (1). For four variants, in vitro results appeared normal (see 
Supplemental Table 1 for a detailed description of the phenotypes of these variants as well as for 
those of previously published cases). 
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Parameters 
Body fat percentage was evaluated with bioelectrical impedance analysis, using the Bodystat 
1500MDD (Bodystat Limited, Isle of Man, British Isles). Testicular and thyroid gland size was 
measured in males using standard ultrasonographic imaging. Descriptions of age-specific reference 
intervals of anthropomorphic measurements, laboratory assays and reference intervals, and definition 
of hormone deficiencies are shown in the Supplemental Methods.  
 
Statistics 
Statistical analyses are described in the Supplemental Methods.
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Results 
Hypothalamic-pituitary-thyroid axis 
All male patients showed central hypothyroidism (Supplemental Fig. 1A) and 59% were prolactin 
deficient (Table 1). The TSH peak 20 minutes after TRH stimulation was decreased in most neonates, 
and in the lower half of the reference range in most other cases (Supplemental Fig. 2). Many patients 
had a small thyroid gland; the volume was <2.5th percentile (7.7 mL) in 74% of cases, and 
“unmeasurably small” in two. Adult thyroid size (n=17) was smaller in patients on long-term 
levothyroxine replacement (median (interquartile range, IQR): 5.6 mL (1.4-6.7 mL), n=11) than in 
untreated patients (7.4 mL (6.4-14.8 mL), n=6) (P=0.021). The two patients with unmeasurable 
thyroid size were 68 and 88 yr old and started treatment with levothyroxine at the age of 6 yr and 30 
yr, respectively. 
Serum SHBG, an indicator of hypothyroidism in the liver, was significantly correlated with FT4 
concentrations in treated and untreated adult patients (r=0.583, P=0.002), also after correction for 
body mass index (BMI) (corrected P=0.003). 
 
Growth and development 
Gestational age was normal, but birth weight was ≥0 SDS in 83% and ≥2.0 SDS in 25% of cases 
(Table 1). Psychomotor development was generally normal, although four received physical therapy 
for problems with gross motor skills described as ‘clumsiness’. Patients with sufficient available data 
showed a consistent, typical growth and pubertal development pattern of slow linear growth and 
delayed bone age during childhood, delayed pubertal testosterone production with subsequent delayed 
pubertal growth spurt and development of secondary sexual characteristics during adolescence, 
normal or early timing of the start of testicular growth, and normal adult height, as reported 
previously (2). Head circumference was slightly increased, being ≥0 SDS in 89% and ≥2 SDS in 20% 
(Supplemental Fig. 3). 
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In adulthood, IGF-1 concentrations tended to be high, being ≥0 SDS in 87% and ≥2 SDS in 20% 
of cases. On the contrary, pediatric IGF-1 concentrations were normal in all (Supplemental Fig. 4A). 
Nine males (14%) had been diagnosed with partial GHD during childhood or adolescence. Seven of 
these are adults now, and six were retested after they reached adult height. The patient that was not 
retested in adulthood showed normal serum IGF-1 concentrations after cessation of rhGH therapy. 
The six that were retested showed normal GH responses in all but one patient, in whom a peak GH of 
1.24 ng/mL (reference range >5 ng/mL (6)) was observed during an insulin tolerance test (ITT) at 16 
yr. He continued rhGH therapy and is now 19 years old (see Supplemental Methods for a description 
of his mutation, p.Val985Ala). Two other adults were first tested for GHD at 79 and 66 yrs of age and 
showed normal GH responses during ITT. 
One patient did not show delayed bone age during childhood, but rather had advanced bone ages 
(+1.9 yr at ages 3.1 and 6.1 yr) and tall stature (2.3 SD higher than target height SDS). At age 10 yr 
his testicular volume was 1.7 SDS for age, while no pubic hair, testosterone or DHEAS production 
were observed. By that time, in the absence of a growth spurt, bone age was just 0.4 yr above 
chronological age, and he was obese (BMI 2.3 SDS). He was treated for central hypothyroidism from 
birth and IGF-1 was always around -1.0 SDS. 
 
Puberty and gonadal function 
GnRH testing was performed in nine pediatric patients aged 0.3-13.5 years yr old (Supplemental 
Table 2). One infant, tested at 3 months of age, showed an LH peak of 37.5 U/L and FSH peak of 22.8 
U/L, consistent with the physiological minipuberty in infants (7). A boy of 6.6 yr old showed enlarged 
testes (3.4 SDS) and a borderline positive GnRH test (LH peak 5.2 U/L, Immulite immunoassay), but 
no other signs of pubertal development were observed in the years thereafter. Hormonal parameters 
were still pre-pubertal at 8 years of age (non-stimulated LH 0.3 U/L, FSH 4.3 U/L, testosterone <0.7 
nmol/L). Five patients aged between 7.3 and 11.6 yr showed no activation of the hypothalamo-
pituitary-gonadal (HPG) axis despite having enlarged (2.8-4.4 SDS) or normal testes for age (0.2-0.5 
SDS) at palpation. Lastly, the first evidently positive GnRH tests were observed in two patients at 
9 
 
 
 
194 
195 
196 
197 
198 
199 
200 
201 
202 
203 
204 
205 
206 
207 
208 
209 
210 
211 
212 
213 
214 
215 
216 
217 
218 
219 
12.7 yr (LH peak 9.4 U/L) and 13.5 yr (LH peak 8.3 U/L, testes >25 mL). In all these patients, 
including those with pubertal GnRH tests, pubic hair and testosterone production (if these data were 
available) were absent, while testicular enlargement (≥4 mL) was observed in two of them as early as 
2.6 yr and 2.8 yr. In most pediatric patients, ultrasonographic testicular volume was in the upper half 
of the reference range, but in 87% of adults it was ≥2.0 SDS (Supplemental Fig. 5). No testicular 
pathology was observed during ultrasonographic examinations, but two patients had suffered from 
testicular torsion at the age of 4 yr and 74 yr. 
Fig. 1 displays (longitudinal) pediatric testosterone values from the entire cohort, showing a late 
start of testosterone rise in most. The GnRH test in thirteen late-pubertal or adult patients (range 16.7-
66.4 yr) showed normal mean LH peaks of 26.3 U/L (SD 8.1 U/L) and mean FSH peaks of 15.5 U/L 
(SD 7.6 U/L). Mean testosterone concentrations in adults were below the reference range median in 
90% of adult patients, as was LH in 93% (Table 2). FSH was normal, but relatively high compared to 
the low LH concentrations, resulting in an increased FSH/LH ratio. Inhibin B concentrations were 
normal, but the inhibin B/FSH ratio was below the reference range median in all adult patients (and 
decreased in 20%). Inhibin B concentrations in adults (n=20) were not significantly correlated to 
ultrasonographic testicular volume (P=0.677), and its correlations with FSH (P=0.060) and 
testosterone (P=0.057) were almost significant.  
Two patients had been treated with testosterone during puberty (one and three years). Fertility was 
preserved in all evaluable individuals, except for one patient who was unable to reproduce and 
diagnosed with azoospermia, and was resistant to treatment with FSH and LH. 
 
Adrenal function 
Fig. 2 shows pediatric DHEAS plasma concentrations, revealing lower concentrations in those with 
prolactin deficiency (B=-1.357 nmol/L, P=0.001, corrected for age). Longitudinal data on DHEAS 
were available in four patients with prolactin deficiency, showing a late biochemical adrenarche 
(DHEAS >1.084 µmol/L (8)) at 13-16 yr. Adrenal steroids from 24-h urine were collected in five 
10 
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patients aged 8.7, 8.8, 10.1, 12.4, and 13.0 yrs. Androgen metabolites (17-ketosteroids) were close to 
the lower limit of the reference range in all patients (Supplemental Fig. 6). 
In adults, DHEA and DHEAS were below the reference range median in nearly all and decreased 
in 40% and 18%, respectively (Table 2). Androstenedione was generally normal, and no association 
between prolactin deficiency and adult adrenal steroid values was observed. 
Cortisol concentrations were normal in all evaluated adult patients, and neither signs nor 
symptoms of hypocortisolism were observed. Hydrocortisone replacement was prescribed to only one 
75 yr old patient, after showing an insufficient cortisol rise after administration of CRH (0.410 
µmol/L, reference range >0.550 µmol/L), but a normal response to synthetic ACTH (0.840 µmol/L). 
Six of the 28 (21%) patients whose adrenal axis was evaluated shortly after birth were diagnosed with 229 
hypocortisolism because of low random cortisol values or abnormal low-dose ACTH testing results. 
However, hydrocortisone replacement could be stopped within a few years in all, after the finding of 
normal random cortisol values or adequate cortisol responses to synthetic ACTH (0.610-0.700 
µmol/L). 
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Metabolic parameters 
Sixty-seven percent of male children were classified as overweight, and 21% as obese. Compared to 
the general population, BMI was >2.0 SDS in 37%. Waist circumference was increased (>2.0 SDS) in 
57%, and fat percentage in 29% (Supplemental Table 3). Lipids were generally normal, although three 
children aged 0.8-3.5 yr showed increased total and LDL-cholesterol (cholesterol 2.7-3.6 SDS, LDL 
2.7-4.5 SDS). All three were obese (BMI 2.2-3.1 SDS), and two were treated with levothyroxine. The 
untreated boy (0.8 yr old) also showed increased triglyceride concentrations (4.03 mmol/L, reference 
range 0.21-2.01 mmol/L), which improved after start of levothyroxine replacement at 1.3 yr (1.22 
mmol/L). BMI-corrected leptin concentrations were slightly increased, as 84% showed concentrations 
≥0.0 SDS and 21% ≥2.0 SDS. Fasting concentrations of glucose, insulin, and C-peptide were 
generally normal. 
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Increased BMI (>25 kg/m2) was observed in 73% of adult males (general Dutch population: 
53.8%, P=0.017 (9)), but obesity (BMI >30.0 kg/m2) was only observed in 17% (general population: 
14.1%, P=0.623). Furthermore, waist circumference was increased (≥94.0 cm) in 60% and fat 
percentage in 20% (Supplemental Table 3). Lipid concentrations were generally normal, as were 
BMI-corrected leptin concentrations, glucose, and insulin, but C-peptide was increased in 40%. FT4 
concentrations were not significantly associated with any of these parameters (average P=0.509). 
Hypertension was diagnosed and treated in four patients (13%), type 2 diabetes mellitus in three 
(10%), and dyslipidemia in four (13%)(all >60.0 yr). 
 
Brain 
Four patients were diagnosed with attention deficit disorder, one with attention deficit hyperactivity 
disorder, one with social deficit hyperactivity disorder (10), and one showed deficits in attention and 
concentration at neuropsychological testing (13 yr old). All of these patients were younger than 25 yr, 
and four had been treated with psychostimulants. One other patient was diagnosed with a pervasive 
developmental disorder – not otherwise specified (PDD-NOS). In eight of 24 available MRI scans (six 
neonates), variable degrees of widening of the cerebrospinal fluid containing spaces were observed. 
The widening was located at the lateral and third ventricle in one, but in the others mostly in the 
peripheral spaces: around the cerebellum in one, frontal in three, and in the basal cistern in three. In 
one of these six patients, however, a frontoparietal hygroma was diagnosed and treated with a 
ventriculoperitoneal shunt after being evaluated for macrocephaly at six months old (head 
circumference 5.1 SDS). In the remaining fourteen patients neuro-imaging showed no abnormalities, 
besides hypoplasia of the corpus callosum in one case. No signs of cognitive impairment were 
observed. 
 
Female carriers 
In female heterozygous carriers, FT4 was below the lower limit in 18%, and in the lower tertile of the 
reference range in 60% (Supplemental Fig. 1B). IGF-1 concentrations were ≥2.0 SDS in 31% 
12 
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(mean±SD: 1.1±1.7, n=42, Supplemental Fig. 4B) and mild prolactin deficiency was present in 22%, 
although no one reported a history of problems with lactation. TRH tests were performed in six adult 
females (three of whom had decreased basal FT4), showing normal or exaggerated TSH peaks at 20 
minutes (8.0-32.4 mU/L; reference range: >2.8 mU/L). Five of ten female carriers with decreased FT4 
started treatment with levothyroxine after initial investigations, and all reported improvement of 
energy levels. Eight adult females underwent thyroid ultrasonography, showing a thyroid volume 
below the reference range median (<10.0 mL) in seven (two were on levothyroxine replacement) and 
<2.5th percentile (<4.8 mL) in two (untreated). No evident relation with X-chromosome inactivation 
was observed, as those with skewed inactivation (5 of 29 informative test results) showed central 
hypothyroidism in only two without hypoprolactinemia. Age at menarche was delayed (>14.5 years 
(11)) in 15 of 48 females (31%) with available data. No correlation was found between FT4 
concentrations and age at menarche, and no fertility issues were reported. Cortisol was normal in all 
females (0.372±0.202 µmol/L; reference range 0.100-0.600 µmol/L). 
Females showed a metabolic profile similar to males, with increased BMI in 55%, waist 
circumference in 57%, and fat percentage in 36% (Supplemental Table 3). Triglycerides, cholesterol, 
HDL, and BMI-corrected leptin were generally normal, but LDL was increased in 37%. Glucose, 
insulin, and C-peptide were generally normal. FT4 concentrations were significantly correlated to 
waist circumference (r=0.345, P=0.022), triglyceride concentrations (r=0.375, P=0.010), and fasting 
glucose (r=0.409, P=0.005). One adult female was treated for hypercholesterolemia (63.9 yr), one for 
hypertension (62.2 yr), and none for diabetes mellitus. 
 
For all characteristics of IGSF1 deficiency in males and females, no clear genotype-phenotype 
relation was observed, and signs and symptoms varied within families with the same mutation.
13 
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Discussion 
The results of this case series of patients with the X-linked IGSF1 deficiency syndrome, the largest to 
date, reveal new symptoms and expand the information on previously reported symptoms. Despite 299 
having been discovered only recently, this syndrome already encompasses more unique mutations and 
patients than all other known genetic causes of isolated central hypothyroidism combined (TSHB (12-
16) and TRHR (17,18)). An overview of the clinical features of IGSF1 deficiency is presented in 
Table 3, and recommendations for genetic evaluation and clinical management are provided in Table 
4. 
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Central hypothyroidism and growth 
Central hypothyroidism remains the key feature of IGSF1 deficiency, being present in all male cases. 
As central hypothyroidism was previously also proposed to be the key feature (1,2), and most new 
index cases were discovered based on this sign, its prevalence might be subject to selection bias. 
Nevertheless, all non-index cases also showed central hypothyroidism. Growth velocity was usually 
decreased and bone age delayed (2), and partial GHD was diagnosed in 14%. We therefore advise 
stringent follow-up of growth, supplemented by IGF-1 concentrations, bone age determination, and 
(primed) GH stimulation tests in case of growth failure. As GHD proved transient in most, but not all, 
patients treated with rhGH, GH stimulation tests should be repeated after reaching adult height.  
 
Pubertal development and adult gonadal functioning 
The pubertal rise in testosterone was often delayed, in contrast to a normal or even advanced start of 
testicular growth. The mechanism of this disharmonious pubertal development as well as the adult 
macroorchidism has not yet been elucidated. However, current data in the limited number of pubertal 
patients studied suggest a combination of both central and testicular causes. A central cause of the 
delayed testosterone rise is supported by slightly delayed activation of the hypothalamic-pituitary-
14 
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gonadal axis in GnRH stimulation tests, with relatively high FSH values that could contribute to 
testicular enlargement (15;16). Additionally, testicular function might be altered through decreased 
penetrance of thyroid hormone in the testis, resulting in early and prolonged proliferation of Sertoli 
cells (causing macroorchidism) and decreased receptivity of Leydig cells to LH (causing delayed 
testosterone rise) (15;16). The normal inhibin B concentrations (a marker of Sertoli cell number and 
stimulated by FSH) despite macroorchidism and relatively high FSH concentrations might indicate 
decreased Sertoli cell function or decreased negative feedback of inhibin B at the pituitary level, 
although previous investigations reported no evidence for the latter (19). We advise to monitor 
pubertal development annually using height, pubic hair staging, testicular volume, and testosterone 
concentrations (when testes reach ≥4 mL). Treatment with testosterone should be considered when 
pubic hair stage 1 and/or prepubertal testosterone concentrations are observed at the age of 14.0 yr or 
greater. We discourage screening for IGSF1 mutations in patients with delayed puberty and a normal 
thyroid function (20). 
 
Neonatal hypocortisolism 
Although hypocortisolism was diagnosed in 21% of newborns (available data in 28 males [41%]), this 337 
condition proved transient within a few years in all. In some newborns hypocortisolism was only 338 
based on randomly measured cortisol concentrations, which may have resulted in overestimation of its 339 
prevalence. Because of these two points, plus the absence of IGSF1 expression in corticotroph cells of 340 
the rat pituitary gland (21), we consider the chance that the adrenal axis is perturbed in IGSF1 341 
deficiency remote. Nevertheless, we cannot rule out true neonatal hypocortisolism, and given the 342 
potentially dangerous nature of this condition we suggest dynamic adrenal axis testing in all newborns 343 
with central hypothyroidism. If adrenal insufficiency is diagnosed, hydrocortisone treatment should be 
initiated before the start of levothyroxine replacement because of the risk of initiating symptomatic 
adrenal insufficiency (22). Consequently, if dynamic testing cannot be performed, prophylactic 
glucocorticoid replacement should be considered just like in other causes of central hypothyroidism 
(23).  
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Brain 
Variable degrees of widening of the liquor containing spaces were observed in 8 of 24 MRI scans. 
However, most findings were in neonates in whom this can be a variation of normal development 
known as benign external hydrocephalus (BEH) (24). BEH is the most prevalent cause of (familial) 
macrocephaly and usually resolves by the age of 2 years although macrocephaly may persist. 
Increased head circumference was indeed observed in 20% of patients, and has also been reported in 
other causes of congenital hypothyroidism (25) and in patients with resistance to thyroid hormone due 
to a mutation in the THRA gene (26). Although one patient was treated for frontoparietal hygroma, we 
do not believe that these results warrant standard cerebral imaging in patients with IGSF1 deficiency 
and a normal head circumference, given the low prevalence and benign character of BEH. In addition, 
we previously reported mild but consistent deficits in attentional control (27), and seven patients 
(10.1%) were diagnosed with disorders related to attention (pediatric population prevalence of 
ADHD: 7.2% (28)). Treating physicians should be aware of these potential problems. Also, problems 
with gross motor skills should be recognized early, as four patients benefited from physical therapy. 
 
Additional symptoms 
First, we observed (very) small thyroid glands, especially in patients with suppressed TSH. This 
finding likely results from decreased TSH signaling (29-33), and warrants caution when patients on 
long-term treatment consider stopping levothyroxine replacement and in pregnant heterozygous 
females. Second, we observed increased birth weight in one-third of patients, in accordance with two 
of six Japanese cases of IGSF1 deficiency (5) as well as with other causes of congenital 
hypothyroidism (34). Third, a late adrenarche was observed in patients with prolactin deficiency, 
although data were limited. Prolactin receptors are highly expressed in the adrenal gland and 
synergize with ACTH to augment adrenal androgen secretion (35-37). Furthermore, experimental 
lowering of prolactin concentrations decreases DHEAS, whereas DHEAS is elevated in 
hyperprolactinemia (38,39). Prolactin deficiency may therefore be considered as the main cause of 
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late adrenarche in IGSF1-deficient patients. An association between adrenal steroids and prolactin 
concentrations was absent in adults. 
 
Treatment 
The degree of hypothyroidism varied, and for all patients it was unknown to what extent FT4 
concentrations were below individual and optimal set-points, and how long-term congenital 
hypothyroidism may have affected this set-point. There are, however, several arguments in favor of 
treatment. We observed prolonged jaundice, growth delay, obesity, and sometimes dyslipidemia in 
untreated children who later responded well to the initiation of treatment (1). In male adults, BMI-
corrected SHBG concentrations (a marker of liver hypothyroidism) were significantly correlated to 
free T4 concentrations, implying suboptimal thyroid hormone exposure in untreated individuals. We 
also observed higher waist circumference, triglycerides, and glucose in females with lower FT4 
concentrations. Male and female adults who started treatment after diagnosis reported major 
improvements in energy levels, as previously described in other hidden forms of central 
hypothyroidism (23), although long-term results in our patients are unavailable. On the other hand, 
untreated adults were generally well-functioning, well-educated, of normal height, rarely showed 
dyslipidemia or cardiovascular disease, and were not more obese than their treated peers. 
Nevertheless, we advise treatment of all children with levothyroxine, commencement of a trial course 
in all male adults and in female adults with low (-normal) thyroxine concentrations, and re-assessment 
of FT4 concentrations in females before and during pregnancy.  
 
Genetic evaluation 
We advise genetic evaluation of all patients with central hypothyroidism of unknown cause for IGSF1 
mutations, especially when accompanied by an X-linked inheritance pattern, prolactin or GH 
deficiency, disharmonious pubertal development, macroorchidism, or delayed adrenarche. As 
asymptomatic adult carriers are likely to benefit from treatment with levothyroxine, family members 
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should be evaluated based on the X-linked inheritance pattern. All children of female carriers (and 
female children of male patients) should be screened at birth with TSH and T4. 
 
In conclusion, this study describes the phenotype of the X-linked IGSF1 deficiency syndrome in the 
largest cohort known to date. The results include new symptoms, as well as an expansion of the 
information on known symptoms, allowing us to formulate recommendations for clinical 
management. 
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Table 1. Basic clinical characteristics of the male study population 
 N Children  N Adults 
Gestational age at birth (wk) 26 40.6 (40.0-41.6)  15 41.0 (39.0-43.0) 
Birth weight (SDS) 31 0.9 (0.2-1.7)*  21 1.2 (0.7-2.4)* 
Head circumference (SDS) 26 0.9 (0.5-1.2)*  25 1.2 (0.8-2.1)* 
Height (SDS) 21 -0.6 (-1.4- -0.2)*f  30 -0.2 (-1.1-0.3) 
Thyroid volume <P50 / <P2.5 21 95% / 67%  17 88% / 82% 
TSH at diagnosis (mU/L)a 32 2.15 (1.53-3.28)  28 1.70 (1.20-2.76) 
Free T4 at diagnosis (pmol/L)b 32 9.1 (8.1-9.6)*  28 9.0 (8.5-9.4)* 
Central hypothyroidism 35 100%  34 100% 
Prolactin deficiency 34 62%  31 55% 
(transient) GH deficiency 35 11%  34 15%g 
IGF-1 (SDS)c 28 -0.6 (-1.0-0.4)  30 1.1 (0.2-1.7)* 
Cortisol (µmol/L)d 32 0.268 (0.213-0.347)  26 0.381 (0.317-0.464) 
Adult testis volume (SDS) - -  23 3.5 (2.4-5.1)* 
Adult thyroid volume (mL)e - -  17 6.5 (4.6-7.1)* 
Data are presented as median (interquartile range). aTSH normal range: 0.30-4.80 mU/L. bNormal ranges 
vary with age and assay. See Supplemental Fig. 1 for free T4 at diagnosis relative to reference range. cIn 
patients not treated with rhGH. dEarly morning fasting withdrawal. In-house reference values for cortisol 
are 0.100-0.600 µmol/L. eReference values in adult men: 19.1 mL (P50) and 7.7 mL (P2.5) (40). fOnly 
Dutch children. gIn these adults, GH deficiency had been transiently present only during childhood and 
adolescence, except for one patient of 19 years old. SDS, standard deviation score. *Different from 
population median at P < 0.05. 
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Table 2. Adrenal and gonadal functioning in male adults 
 N  Reference range 
Age (y) 32 30.9 (23.4-66.3)  
LH (U/L) 29 3.3 ± 1.5* 2.0-9.0 
FSH (U/L) 29 8.2 ± 6.5 1.5-12.5 
FSH / LH ratio 29 2.2 (1.8-2.7)* 0.7-1.2 
Testosterone (nmol/L) 31 14.0 ± 5.0* 8.0-31.0 
SHBG (nmol/L) 25 29.6 ± 15.5* 20-55 
Inhibin B (ng/L) 20 253.6 ± 111.0 150-400 
Inhibin B / FSH ratio 20 31.5 (17.2-55.6)* 15-303 
AMH (µg/L) 21 7.0 (2.7-13.0) 2.0-14.0 
Androstenedione (nmol/L) 24 6.3 (3.4-9.0) 2.0-10.0 
DHEA (nmol/L) 20 9.7 (5.7-19.3)* 7.0-60.0 
DHEAS (µmol/L) 22 3.3 (1.3-4.9)* 2.0-15.0 
Data are presented as median (interquartile range) or mean ± SD. AMH, Anti-
Müllerian hormone; DHEA(S), dehydroepiandrosterone (sulphate). *Different 
from population median at P< 0.05. 
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Table 3. Clinical features of the X-linked IGSF1 deficiency syndrome 
Hemizygous males  
Central hypothyroidism 100% 
Low-normal testosterone concentrations in adulthood 88% 
Adult macroorchidism 88% 
Delayed pubertal testosterone rise, early/normal timing of testicular growth 75%a 
Mild problems with attentional control 75%a 
Small thyroid gland 74% 
Increased waist circumference in adults 59% 
Prolactin deficiency 61% 
Late biochemical adrenarche 50%a 
Increased waist circumference in children 57% 
Decreased DHEA in adulthood 40% 
Benign external hydrocephalus 33%a 
Increased birth weight 26% 
Hypocortisolism in infancy 21% 
Increased IGF-1 concentrations in adulthood 20% 
Increased head circumference 20% 
Growth hormone deficiency in childhood 16% 
  
Heterozygous females  
Delayed age at menarche 31% 
Prolactin deficiency (non-symptomatic) 22% 
Central hypothyroidism 18% 
Based on reported data from current study and (1,3-5). aEstimated based on limited data 
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Table 4. Recommendations for clinical management of IGSF1 deficiency 
Indications for mutational analysis of IGSF1 
Central hypothyroidism of unknown cause, especially when accompanied by: 
- X-linked inheritance pattern 
- Deficiency of prolactin or GH 
- Disharmonious pubertal development, macroorchidism, or delayed adrenarche 
Screen appropriate family members after a mutation is discovered. 
 
Diagnosis and follow-up Children  Adults 
 Diagnosis Follow-up Transition Diagnosis Follow-up 
Males      
History, physical examination Xa Xa X Xb Xb 
FT4, TSH X Xc X X Xc 
Testosterone X annual if testes ≥4 mL X X  
Prolactin X   X  
Dynamic adrenal axis testing Xd     
Cortisol (early a.m.)    Xe  
IGF-1 X c  X  
Cholesterol, TG, HDL, LDL, glucose X c X X c 
If growth failure or low IGF-1:      
(Primed) GH stimulation test, hand X-ray X X f   
      
Females      
History, physical examination Xa   Xb  
FT4, TSH X Xg  X h 
Cholesterol, TG, HDL, LDL, glucose X c  X c 
 
Treatment 
Levothyroxine In all male children. Trial course in male adults, and in females with decreased free T4 or 
low-normal free T4 in combination with features suggestive of tissue hypothyroidism. 
Hydrocortisone In neonates with impaired cortisol response in low-dose ACTH test (<0.550 µmol/L). Re-
evaluate after one year 
rhGH In case of >1.0 SD deviation of growth, height <-2 SD, or low growth velocity, and impaired 
GH response in (primed) GH stimulation test 
Testosterone In case of a delay in pubertal development in males (pubic hair stage 1 and/or prepubertal 
testosterone at 14.0 yr) 
aHeight, weight, head circumference, pubic hair, testicular volume, heart rate. Periodic evaluation at the 
discretion of the treating physician. 
bBMI, waist circumference, signs and symptoms of hypothyroidism and, if treated with levothyroxine, of 
hyperthyroidism. Periodic evaluation at the discretion of the treating physician. 
cFollow-up at the discretion of the treating physician. 
dDynamic testing may be preceded by randomly measured plasma or serum cortisol concentrations. Sufficiently 
high concentrations make central adrenal insufficiency unlikely. However, low concentrations do not prove 
adrenal insufficiency. In case of a low random cortisol concentration in a neonate we suggest to perform a low-
dose ACTH test. If abnormal (cortisol response <0.550 µmol/L), then treat with hydrocortisone. Re-evaluate 
after one year. 
eSufficiently high concentrations make central adrenal insufficiency unlikely. A low concentration warrants 
dynamic adrenal axis testing. 
fRepeat GH stimulation test at transition in patients treated for GH deficiency. 
gAge 0-3 yr: at least yearly, also if hypothyroidism is absent. Age 4-18 yr: at discretion of treating physician. 
hPreconception and during pregnancy. If hypothyroid, follow-up at the discretion of the treating physician. 
29 
 
 
 
TG, triglycerides; LT4, levothyroxine. 
Figure legends 
Figure 1. Testosterone concentrations in male patients. Lines represent longitudinal data and dots 
individual patients. Reference intervals were derived from Andersson et al. (41). 
 
Figure 2. DHEAS concentrations in male patients around the age of biochemical adrenarche (1.084 
µmol/L, dotted line). Lines represent longitudinal data, and the larger diamonds/dots are data from 
individual patients. Smoothed reference intervals were derived from Elmlinger et al. (42).  
 
 
 
